Free Trial
OTCMKTS:VXRT

Vaxart Q1 2026 Earnings Report

Vaxart logo
$0.70 -0.04 (-5.41%)
As of 12:18 PM Eastern
Upcoming Event
Earnings Conference Call
Vaxart Q1 2026
00:00 / 00:00
Live Transcript
Follow Audio

Vaxart EPS Results

Actual EPS
$0.02
Consensus EPS
$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Vaxart Revenue Results

Actual Revenue
$39.23 million
Expected Revenue
$65.50 million
Beat/Miss
Missed by -$26.27 million
YoY Revenue Growth
N/A

Vaxart Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Friday, May 8, 2026
Conference Call Time
4:30PM ET

Upcoming Earnings

Vaxart's Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 8, 2026 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vaxart Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Vaxart Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxart? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxart and other key companies, straight to your email.

About Vaxart

Vaxart (OTCMKTS:VXRT) is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens.

Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness.

View Vaxart Profile